CLASSIFICATION
Glycoprotein Cytokine
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Drogsan
WAREHOUSE
International Warehouse 2
SUBSTANCE
Erythropoietin
Introducing Dropoetin, a vital therapy designed for the effective management of anemia related to chronic kidney failure in both pediatric and adult patients undergoing hemodialysis and peritoneal dialysis. This remarkable medication is also indicated for adult patients experiencing severe renal-origin anemia with clinical symptoms, even if they are not yet on dialysis.
Furthermore, Dropoetin plays a crucial role in treating anemia and minimizing the need for blood transfusions in adult cancer patients?excluding those with myeloid malignancies?who are undergoing chemotherapy.
For adults living with HIV and receiving zidovudine treatment, Dropoetin is recommended for those with endogenous levels at or below 500 mU/ml, ensuring comprehensive care.
In adult patients with moderate anemia (characterized by hematocrit levels of 33-39% and hemoglobin levels between 10-13 g/dL), Dropoetin supports autologous blood collection in predeposit programs. This reduces the likelihood of requiring allogeneic blood transfusions during major elective surgeries, especially when the anticipated blood loss exceeds what can be collected through autologous methods without Dropoetin. Treatment should be considered when blood conservation options are unavailable or inadequate for surgeries likely to require 4 or more units for females or 5 or more units for males.
Dropoetin also enhances red blood cell production during the perisurgical period, minimizing the need for allogeneic blood transfusions and correcting postoperative anemia in adult patients undergoing major elective orthopedic surgeries. Its use is restricted to patients with moderate anemia (hemoglobin levels of 10-13 g/dL) who lack access to an autologous donation program and are expected to experience moderate blood loss (900 to 1800 ml).
Additionally, Dropoetin is effective for treating anemia in patients with Low or Intermediate-1 risk Myelodysplastic Syndrome (MDS), specifically targeting those with hemoglobin levels below 10 g/dL.
How to Use Dropoetin
Administer Dropoetin exactly as prescribed by your healthcare provider. Always consult the medicine label for precise dosage instructions. Accompanied by a Medication Guide, be sure to read and re-read it with each prescription refill.
Typically, Dropoetin is given via injection in a clinical setting. If you are self-administering at home, healthcare professionals will provide thorough instructions. Ensure you fully comprehend the administration process and adhere to the techniques you've learned. For any questions, don't hesitate to reach out to your healthcare provider.
When preparing your dose, follow the outlined protocol to prevent contamination of the vial, syringe, or medication. Avoid touching the rubber stopper of the vial or the syringe needle with your fingers.
Double-check your dose before injection. Do not shake Dropoetin and refrain from using it if it appears shaken or frozen. Avoid diluting or mixing it with other solutions unless specifically directed by your doctor.
If using a single-dose vial, dispose of any remaining medication after administering your dose. If you need guidance about single-dose vials, consult your doctor, pharmacist, or healthcare provider.
Ensure Dropoetin is clear and free of particles; do not use it if the vial is cracked or damaged. Store this product, along with syringes and needles, out of reach of children and pets. Avoid reusing needles or syringes, and inquire about proper disposal methods with your healthcare provider to comply with local regulations.
Continue using Dropoetin even if you feel well, and do not skip any doses. If you miss a dose, contact your doctor promptly. For any inquiries regarding Dropoetin?s use, your healthcare provider is always available to assist.
Dropoetin Side Effects
Be aware of the following serious adverse reactions detailed in other sections of the label:
- Increased mortality
- Myocardial infarction
- Stroke
- Thromboembolism
- Increased mortality and/or risk of tumor progression or recurrence in cancer patients
- Hypertension
- Seizures
- PRCA
- Severe allergic reactions